Correlation of circulating endoglin with clinical outcome in biliary atresia

European Journal of Pediatric Surgery

Volumn 20, Issue 4, 2010, Pages 237-241

  Preativatanyou, K ^a   Honsawek, Sittisak ^a   Chongsrisawat, V ^a   Vejchapipat, P ^a   Theamboonlers, A ^b   Poovorawan, Y ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

biliary atresia; clinical outcome; endoglin; jaundice

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; ENDOGLIN; GAMMA GLUTAMYLTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE DUCT ATRESIA; BILIRUBIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; JAUNDICE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PORTOENTEROSTOMY; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

ALANINE TRANSAMINASE; ANASTOMOSIS, ROUX-EN-Y; ANTIGENS, CD; BILIARY ATRESIA; BILIRUBIN; BIOLOGICAL MARKERS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PORTOENTEROSTOMY, HEPATIC; POSTOPERATIVE PERIOD; PROGNOSIS; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX;

EID: 77955884927     PISSN: 09397248     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0030-1249695     Document Type: Article

References (27)

1. A-Kader HH, Abdel-Hameed A, Al-Shabrawi M, et al. Is biliary atresia an autoimmune disease? Eur J Gastroenterol Hepatol 2003 15 447
2. Asanza CG, García-Monzón C, Clemente G, et al. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. Hepatology 1997 26 755-763
3. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999 274 584-594
4. Bissell DM, Roulot D, George J. Transforming growth factor and the liver. Hepatology 2001 34 859-867
5. Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992 267 19027-19030
6. Clemente M, Núñez O, Lorente R, et al. Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat 2006 13 625-632
7. Davenport M. Biliary atresia. Semin Pediatr Surg 2005 14 42-48
8. Dharmapatni AA, Smith MD, Ahern MJ, et al. The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 2001 19 275-282
9. Diez-Marques L, Ortega-Velazquez R, Langa C, et al. Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta 2002 1587 36-44
10. Díaz-Gil JJ, García-Monzón C, Rúa C, et al. The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats. Histol Histopathol 2008 23 583-591
11. García-Monzón C, Martín-Pérez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000 33 716-724
12. García-Monzón C, Sánchez-Madrid F, García-Buey L, et al. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995 108 231-241
13. Graulich W, Nettelbeck DM, Fischer D, et al. Cell type specificity of the human endoglin promoter. Gene 1999 227 55-62
14. Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in Hepatic fibrosis. Front Biosci 2002 7 D793-D807
15. Honsawek S, Chongsrisawat V, Vejchapipat P, et al. Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters. Pediatr Surg Int 2005 21 73-77
16. Honsawek S, Chongsrisawat V, Vejchapipat P, et al. Association of serum levels of tissue inhibitors of metalloproteinase-1 with clinical outcome in children with biliary atresia. Asian Pac J Allergy Immunol 2006 24 161-166
17. Honsawek S, Chongsrisawat V, Vejchapipat P, et al. Elevation of serum stem-cell factor in postoperative biliary atresia. Pediatr Int 2007 49 888-893
18. Honsawek S, Chongsrisawat V, Vejchapipat P, et al. High levels of serum basic fibroblast growth factor in children with biliary atresia. Hepatogastroenterology 2008 55 1184-1188
19. Karrer FM, Price MR, Bensard DD. Long-term results with the Kasai operation for biliary atresia. Arch Surg 1996 131 493-496
20. Kobayashi H, Stringer MD. Biliary atresia. Semin Neonatol 2003 8 383-391
21. Letamendía A, Lastres P, Botella LM, et al. Role of endoglin in cellular responses to transforming growth factor-: A comparative study with betaglycan. J Biol Chem 1998 273 33011-33019
22. Massagué J, Attisano SL, Wrana SL. The TGF- family and its composite receptors. Trends Cell Biol 1994 4 172-178
23. Vejchapipat P, Theamboonlers A, Chaokhonchai R, et al. Serum hepatocyte growth factor and clinical outcome in biliary atresia. J Pediatr Surg 2004 39 1045-1049
24. Vejchapipat P, Theamboonlers A, Poomsawat S, et al. Serum transforming growth factor-beta 1 and epidermal growth factor in biliary atresia. Eur J Pediatr Surg 2008 18 415-418
25. Westphal JR, Willems HW, Schalkwijk CJ, et al. A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 1993 100 27-34
26. Yagmur E, Rizk M, Stanzel S, et al. Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. Eur J Gastroenterol Hepatol 2007 19 755-761
27. Yu D, Zhuang L, Sun X, et al. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer 2007 7 122